Merck serono to expand research and development presence in china - news release - november 23, 2009
November 23, 2009
Merck Serono to Expand Research and Development Presence in China
• China’s research and development organization will become the fourth
key R&D hub for Merck Serono worldwide
• Merck Serono plans to invest more than 150 Mio €
Geneva, Switzerland, November 23, 2009 – Merck Serono, a division of Merck KGaA,
Darmstadt, Germany, announced today plans to strengthen its global research and
development (R&D) capabilities by establishing a global R&D center in Beijing, China.
Merck Serono is planning to invest more than 150 Mio € and create more than 200 new
qualified jobs over the next four years to set up the China R&D center and conduct
“The creation of the China R&D center marks a new milestone in Merck Serono’s
commitment to China, where there is a rising demand for more healthcare options,”
said Elmar Schnee, President of Merck Serono. “We are committed to investing in
areas that can help China to address some of its public health needs that currently are
“China is a country with talented scientists and high-quality research,” added Bernhard
Kirschbaum, Executive Vice President, Research and Development for Merck Serono.
“We will recruit more R&D talent in China and build a world-class organization in China
that will extend our global R&D expertise and capabilities.”
The China R&D organization will become one of the key R&D hubs for Merck Serono
worldwide. Key hubs so far are Germany, Switzerland and the United States.
The China team will lead drug development for China and other Asian countries, for
local clinical trials as well as for the participation in global clinical trials. The team also
will ensure the management of collaborations with research institutions in China and
continue to look for partnerships with local academic institutions and companies.
Research activities conducted in the China R&D center will mainly focus on biomarker
research including pharmacogenomics and bioanalytics activities.
Merck Serono already has some research collaborations in China and plans to further
develop its collaboration network and build its R&D strategy on more innovation
opportunities by tapping into the Chinese scientific expertise.
Merck Serono China currently employs more than 1,000 persons nationwide. Merck
Serono China offers a portfolio of innovative medicines, including the division’s leading
brands serving patients with cancer (Erbitux®), multiple sclerosis (Rebif®), infertility
(Gonal-f®), endocrine and metabolic disorders (Saizen®), as well as cardiometabolic
About Merck Serono
Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt,
Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck
Serono discovers, develops, manufactures and markets innovative small molecules and
biopharmaceuticals to help patients with unmet medical needs. In the United States and Canada, EMD
Serono operates through separately incorporated affiliates.
Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis
(Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alpha), endocrine and metabolic disorders
(Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride) as well as cardiometabolic
diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products are
available in all markets.
With an annual R&D expenditure of around € 1bn, Merck Serono is committed to growing its business in
specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and
endocrinology, as well as new areas potentially arising out of research and development in autoimmune
and inflammatory diseases. About Merck
Merck is a global pharmaceutical and chemical company with total revenues of € 7.6 billion in 2008, a
history that began in 1668, and a future shaped by approximately 33,000 employees in 60 countries. Its
success is characterized by innovations from entrepreneurial employees. Merck's operating activities come
under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and
free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was
expropriated and has been an independent company ever since.
For more information, please visit www.merckserono.com or
The reporting requirements outlined in the Economic Development Area Report form are derived from the Economic Development Area Tax Increment Allocation Act [20 ILCS 620et. seq.] For any problems regarding the preparation or submission of the TIF Report forms, please call the Local Government Assistance Hotline at (877) 304-3899 or Bill Nambo, at 312-814-0969. HOW TO FIND AND DO
Eligibility Statement : All International students registered for credit courses are automatically enrolled in this insurance Plan at registration, unless proof of Effective and Termination Dates : This Insurance Plan becomes effective at 12:01 am on August 15, 2013 . Coverage becomes effective on the first day of the period for which premium is paid or the date the enrollment